Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein SA pseudogene 35 (RPSAP35) is annotated as a pseudogene related to the RPSA gene, which encodes ribosomal protein SA—a protein that functions as both a component of the ribosomal small subunit and a high-affinity laminin receptor at the cell surface. Pseudogenes such as RPSAP35 do not produce functional proteins and are generally considered to be non-coding genomic sequences derived from retrotransposition or duplication events involving protein-coding genes. Unlike functional ribosomal proteins or receptors, RPSAP35 does not participate in canonical protein synthesis, cell signaling, or serve as a receptor, and there is no documented evidence that it plays a role in disease, drug response, or as a biomarker. Essential context: Ribosomal protein SA (RPSA) is a multifunctional protein involved in both ribosomal function and extracellular matrix signaling, implicated in cancer progression and laminin binding. However, RPSAP35 is a pseudogene and does not share these roles. Pseudogenes are typically excluded from lists of bona fide drug targets, and there is no evidence or database entry suggesting that RPSAP35 has any therapeutic relevance.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein SA pseudogene 35 (RPSAP35).